Filtered By:
Cancer: Leukemia
This page shows you your search results in order of relevance. This is page number 20.
Order by Relevance | Date
Total 28070 results found since Jan 2013.
Leukemia Cutis as an Early Presentation or Relapsing Manifestation of Chronic Lymphocytic Leukemia (CLL)
CONCLUSION: Patients with early-stage and localized leukemia cutis can benefit from observation alone strategy, while intervention in young patients with advanced disease is warranted. Skin infiltration by CLL does not affect prognosis, as most patients attained complete or partial remission with a very low progression rate.PMID:33988158 | DOI:10.23750/abm.v92i2.10763
Source: Acta Bio-Medica : Atenei Parmensis - May 14, 2021 Category: General Medicine Authors: Mahmood B Aldapt Mohamed Yassin Source Type: research
An evaluation of venetoclax in combination with azacitidine, decitabine, or low-dose cytarabine as therapy for acute myeloid leukemia
Expert Rev Hematol. 2021 Jun 2. doi: 10.1080/17474086.2021.1938533. Online ahead of print.ABSTRACTINTRODUCTION: Older patients with acute myeloid leukemia (AML) ineligible for conventional chemotherapy have historically received low-intensity treatments, if any, and have had dismal outcomes. Recent phase III data have demonstrated significant efficacy of venetoclax-based combinations and have begun to address the unmet need in this patient population. As venetoclax-based combinations become increasingly used in the clinical setting, it is important to understand their development, current use, and future directions.AREAS C...
Source: Expert Review of Hematology - June 2, 2021 Category: Hematology Authors: Tamer A Othman Matthew E Tenold Benjamin N Moskoff Tali Azenkot Brian A Jonas Source Type: research
L-asparaginase production review: bioprocess design and biochemical characteristics
Appl Microbiol Biotechnol. 2021 Jun 1. doi: 10.1007/s00253-021-11359-y. Online ahead of print.ABSTRACTIn the past decades, the production of biopharmaceuticals has gained high interest due to its great sensitivity, specificity, and lower risk of negative effects to patients. Biopharmaceuticals are mostly therapeutic recombinant proteins produced through biotechnological processes. In this context, L-asparaginase (L-asparagine amidohydrolase, L-ASNase (E.C. 3.5.1.1)) is a therapeutic enzyme that has been abundantly studied by researchers due to its antineoplastic properties. As a biopharmaceutical, L-ASNase has been used in...
Source: Applied Microbiology and Biotechnology - June 1, 2021 Category: Microbiology Authors: Daniel Castro Ana Sofia C Marques Mafalda R Almeida Gabriela B de Paiva Heitor B S Bento Danielle B Pedrolli Mara G Freire Ana P M Tavares Val éria C Santos-Ebinuma Source Type: research
Leukemia Cutis as an Early Presentation or Relapsing Manifestation of Chronic Lymphocytic Leukemia (CLL)
CONCLUSION: Patients with early-stage and localized leukemia cutis can benefit from observation alone strategy, while intervention in young patients with advanced disease is warranted. Skin infiltration by CLL does not affect prognosis, as most patients attained complete or partial remission with a very low progression rate.PMID:33988158 | DOI:10.23750/abm.v92i2.10763
Source: Acta Bio-Medica : Atenei Parmensis - May 14, 2021 Category: General Medicine Authors: Mahmood B Aldapt Mohamed Yassin Source Type: research
An evaluation of venetoclax in combination with azacitidine, decitabine, or low-dose cytarabine as therapy for acute myeloid leukemia
Expert Rev Hematol. 2021 Jun 2. doi: 10.1080/17474086.2021.1938533. Online ahead of print.ABSTRACTINTRODUCTION: Older patients with acute myeloid leukemia (AML) ineligible for conventional chemotherapy have historically received low-intensity treatments, if any, and have had dismal outcomes. Recent phase III data have demonstrated significant efficacy of venetoclax-based combinations and have begun to address the unmet need in this patient population. As venetoclax-based combinations become increasingly used in the clinical setting, it is important to understand their development, current use, and future directions.AREAS C...
Source: Expert Review of Hematology - June 2, 2021 Category: Hematology Authors: Tamer A Othman Matthew E Tenold Benjamin N Moskoff Tali Azenkot Brian A Jonas Source Type: research
Leukemia Cutis as an Early Presentation or Relapsing Manifestation of Chronic Lymphocytic Leukemia (CLL)
CONCLUSION: Patients with early-stage and localized leukemia cutis can benefit from observation alone strategy, while intervention in young patients with advanced disease is warranted. Skin infiltration by CLL does not affect prognosis, as most patients attained complete or partial remission with a very low progression rate.PMID:33988158 | DOI:10.23750/abm.v92i2.10763
Source: Acta Bio-Medica : Atenei Parmensis - May 14, 2021 Category: General Medicine Authors: Mahmood B Aldapt Mohamed Yassin Source Type: research
An evaluation of venetoclax in combination with azacitidine, decitabine, or low-dose cytarabine as therapy for acute myeloid leukemia
Expert Rev Hematol. 2021 Jun 2. doi: 10.1080/17474086.2021.1938533. Online ahead of print.ABSTRACTINTRODUCTION: Older patients with acute myeloid leukemia (AML) ineligible for conventional chemotherapy have historically received low-intensity treatments, if any, and have had dismal outcomes. Recent phase III data have demonstrated significant efficacy of venetoclax-based combinations and have begun to address the unmet need in this patient population. As venetoclax-based combinations become increasingly used in the clinical setting, it is important to understand their development, current use, and future directions.AREAS C...
Source: Expert Review of Hematology - June 2, 2021 Category: Hematology Authors: Tamer A Othman Matthew E Tenold Benjamin N Moskoff Tali Azenkot Brian A Jonas Source Type: research
Leukemia Cutis as an Early Presentation or Relapsing Manifestation of Chronic Lymphocytic Leukemia (CLL)
CONCLUSION: Patients with early-stage and localized leukemia cutis can benefit from observation alone strategy, while intervention in young patients with advanced disease is warranted. Skin infiltration by CLL does not affect prognosis, as most patients attained complete or partial remission with a very low progression rate.PMID:33988158 | DOI:10.23750/abm.v92i2.10763
Source: Acta Bio-Medica : Atenei Parmensis - May 14, 2021 Category: General Medicine Authors: Mahmood B Aldapt Mohamed Yassin Source Type: research
An evaluation of venetoclax in combination with azacitidine, decitabine, or low-dose cytarabine as therapy for acute myeloid leukemia
Expert Rev Hematol. 2021 Jun 2. doi: 10.1080/17474086.2021.1938533. Online ahead of print.ABSTRACTINTRODUCTION: Older patients with acute myeloid leukemia (AML) ineligible for conventional chemotherapy have historically received low-intensity treatments, if any, and have had dismal outcomes. Recent phase III data have demonstrated significant efficacy of venetoclax-based combinations and have begun to address the unmet need in this patient population. As venetoclax-based combinations become increasingly used in the clinical setting, it is important to understand their development, current use, and future directions.AREAS C...
Source: Expert Review of Hematology - June 2, 2021 Category: Hematology Authors: Tamer A Othman Matthew E Tenold Benjamin N Moskoff Tali Azenkot Brian A Jonas Source Type: research
Clinical outcomes of interferon therapy for polycythemia vera and essential thrombocythemia: a systematic review and meta-analysis
In conclusion, interferon therapy provided high rates of hematological and molecular response for patients with PV and ET and was associated with a favorable prognosis.PMID:34091876 | DOI:10.1007/s12185-021-03171-1
Source: International Journal of Hematology - June 6, 2021 Category: Hematology Authors: Wenjing Gu Renchi Yang Zhijian Xiao Lei Zhang Source Type: research
Leukemia Cutis as an Early Presentation or Relapsing Manifestation of Chronic Lymphocytic Leukemia (CLL)
CONCLUSION: Patients with early-stage and localized leukemia cutis can benefit from observation alone strategy, while intervention in young patients with advanced disease is warranted. Skin infiltration by CLL does not affect prognosis, as most patients attained complete or partial remission with a very low progression rate.PMID:33988158 | DOI:10.23750/abm.v92i2.10763
Source: Acta Bio-Medica : Atenei Parmensis - May 14, 2021 Category: General Medicine Authors: Mahmood B Aldapt Mohamed Yassin Source Type: research
An evaluation of venetoclax in combination with azacitidine, decitabine, or low-dose cytarabine as therapy for acute myeloid leukemia
Expert Rev Hematol. 2021 Jun 2. doi: 10.1080/17474086.2021.1938533. Online ahead of print.ABSTRACTINTRODUCTION: Older patients with acute myeloid leukemia (AML) ineligible for conventional chemotherapy have historically received low-intensity treatments, if any, and have had dismal outcomes. Recent phase III data have demonstrated significant efficacy of venetoclax-based combinations and have begun to address the unmet need in this patient population. As venetoclax-based combinations become increasingly used in the clinical setting, it is important to understand their development, current use, and future directions.AREAS C...
Source: Expert Review of Hematology - June 2, 2021 Category: Hematology Authors: Tamer A Othman Matthew E Tenold Benjamin N Moskoff Tali Azenkot Brian A Jonas Source Type: research
Clinical outcomes of interferon therapy for polycythemia vera and essential thrombocythemia: a systematic review and meta-analysis
In conclusion, interferon therapy provided high rates of hematological and molecular response for patients with PV and ET and was associated with a favorable prognosis.PMID:34091876 | DOI:10.1007/s12185-021-03171-1
Source: International Journal of Hematology - June 6, 2021 Category: Hematology Authors: Wenjing Gu Renchi Yang Zhijian Xiao Lei Zhang Source Type: research
Leukemia Cutis as an Early Presentation or Relapsing Manifestation of Chronic Lymphocytic Leukemia (CLL)
CONCLUSION: Patients with early-stage and localized leukemia cutis can benefit from observation alone strategy, while intervention in young patients with advanced disease is warranted. Skin infiltration by CLL does not affect prognosis, as most patients attained complete or partial remission with a very low progression rate.PMID:33988158 | DOI:10.23750/abm.v92i2.10763
Source: Acta Bio-Medica : Atenei Parmensis - May 14, 2021 Category: General Medicine Authors: Mahmood B Aldapt Mohamed Yassin Source Type: research
